Growth factor membranes in treatment of multiple gingival recessions: a randomized clinical trial.

OBJECTIVE: The aim of this study was to assess the clinical effects of concentrated growth factor (CGF) in combination with coronally advanced flap (CAF) compared with platelet rich fibrin (PRF)+CAF for the treatment of multiple adjacent gingival recessions (GRs). METHOD AND MATERIALS: 18 subjects with total of 76 Type I GRs in the maxilla were included. Recessions were randomly treated according to a split-mouth design by means of CGF+CAF (39 defects, CGF side), or PRF+CAF (37 defects, PRF side). Clinical outcomes were evaluated at 6 months. RESULTS: The mean root coverage was 86.32% and 80.86%, and complete root coverage was 61.53% (24/39) and 51.35% (19/37) for CGF side and PRF side, respectively, at 6 months. Statistically significant gains were observed in the terms of clinical attachment level, recession depth, keratinized gingiva width, gingival thickness, and recession width in the both sides at 6 months compared to baseline values; no statistically significant difference was observed in these parameters between the two sides at 6 months. CONCLUSIONS: According to results, the use of CGF+CAF was not superior to PRF+CAF in providing additional benefits in clinical parameters. Keratinized gingiva width and gingival thickness significantly increased with the use of CGF and PRF membranes together with CAF.

Chemerin as a Novel Crevicular Fluid Marker of Patients With Periodontitis and Type 2 Diabetes Mellitus.

BACKGROUND: The objectives of the present study are to: 1) determine whether gingival crevicular fluid (GCF) chemerin is a novel predictive marker for patients with chronic periodontitis (CP) with and without type 2 diabetes mellitus (t2DM); 2) analyze the relationship between chemerin and interleukin (IL)-6 in periodontally healthy individuals and in patients with CP and with and without t2DM; and 3) evaluate the effect of non-surgical periodontal therapy on GCF chemerin levels. METHODS: Eighty individuals were split into four groups: 20 who were systemically and periodontally healthy (CTRL), 20 with t2DM and periodontally healthy (DM-CTRL), 20 systemically healthy with CP (CP), and 20 with CP and t2DM (DM-CP). Individuals with periodontitis were treated with non-surgical periodontal therapy. GCF sampling procedures and clinical periodontal measures were performed before and 6 weeks after treatment. Enzyme-linked immunosorbent assay was used to measure chemerin and IL-6 levels. RESULTS: Greater values for GCF chemerin and IL-6 levels were found in CP groups than in periodontally healthy groups, in DM-CP than in CP, and in DM-CTRL than in CTRL (P <0.008). GCF chemerin and IL-6 levels decreased following therapy in CP groups (P <0.02). A comprehensive overview of all groups showed a statistically significant positive correlation of chemerin with IL-6, glycated hemoglobin, sampled-site clinical attachment level, and gingival index (P <0.05). CONCLUSIONS: In this study, periodontitis and t2DM induced aberrant secretion of chemerin, and non-surgical periodontal therapy influenced the decrease of GCF chemerin levels in patients with CP with and without t2DM. Furthermore, it suggests GCF chemerin levels may be considered a potential proinflammatory marker for diabetes, periodontal disease, and treatment outcomes.